cabergoline Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
ergot alkaloid derivatives 460 81409-90-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cabergoline
  • dostinex
  • galastop
  • cabaser
  • cabaseril
An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.
  • Molecular weight: 451.62
  • Formula: C26H37N5O2
  • CLOGP: 4.17
  • LIPINSKI: 0
  • HAC: 7
  • HDO: 2
  • TPSA: 71.68
  • ALOGS: -3.85
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 mg O
3 mg O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 3 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.01 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 65 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Dec. 23, 1996 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Aortic valve incompetence 168.76 16.02 55 7458 5915 46672634
Blood growth hormone increased 165.87 16.02 32 7481 380 46678169
Insulin-like growth factor increased 162.59 16.02 35 7478 738 46677811
Blood prolactin increased 110.91 16.02 34 7479 2993 46675556
Ovarian hyperstimulation syndrome 109.13 16.02 34 7479 3158 46675391
Mitral valve incompetence 79.51 16.02 45 7468 18807 46659742
Pituitary tumour 78.40 16.02 20 7493 895 46677654
Insulin-like growth factor decreased 72.53 16.02 16 7497 379 46678170
Pituitary tumour benign 66.36 16.02 20 7493 1661 46676888
Cardiac valve disease 60.02 16.02 23 7490 3961 46674588
Parkinson's disease 59.42 16.02 18 7495 1521 46677028
Abortion spontaneous 59.26 16.02 52 7461 43594 46634955
Acromegaly 57.62 16.02 10 7503 62 46678487
Coronary artery dissection 49.04 16.02 13 7500 677 46677872
Pituitary haemorrhage 48.81 16.02 9 7504 82 46678467
Blood prolactin decreased 48.43 16.02 8 7505 35 46678514
Prolactin-producing pituitary tumour 46.40 16.02 9 7504 110 46678439
Needle issue 45.33 16.02 21 7492 5783 46672766
Tricuspid valve incompetence 40.37 16.02 26 7487 13691 46664858
Mastitis 37.26 16.02 14 7499 2284 46676265
Mediastinal fibrosis 36.96 16.02 6 7507 23 46678526
Gambling disorder 36.85 16.02 12 7501 1284 46677265
Aortic valve sclerosis 35.20 16.02 11 7502 1031 46677518
Delusion 34.89 16.02 22 7491 11166 46667383
Cerebrospinal fluid leakage 32.91 16.02 10 7503 853 46677696
Inappropriate schedule of product administration 32.67 16.02 46 7467 64967 46613582
Pneumocephalus 32.62 16.02 7 7506 145 46678404
Bite 30.97 16.02 8 7505 376 46678173
Mitral valve disease 30.58 16.02 12 7501 2200 46676349
Compulsive shopping 29.41 16.02 9 7504 786 46677763
Hypogonadism 29.37 16.02 6 7507 97 46678452
Neoplasm progression 28.83 16.02 28 7485 26655 46651894
Exposure during pregnancy 28.11 16.02 57 7456 108155 46570394
Hallucination 27.58 16.02 37 7476 49914 46628635
Hyperprolactinaemia 27.31 16.02 12 7501 2920 46675629
Sudden onset of sleep 26.84 16.02 8 7505 639 46677910
Overweight 26.62 16.02 12 7501 3101 46675448
Diarrhoea 26.23 16.02 31 7482 559571 46118978
Kounis syndrome 25.76 16.02 9 7504 1193 46677356
Pituitary tumour recurrent 25.35 16.02 5 7508 67 46678482
Camptocormia 24.86 16.02 6 7507 213 46678336
Pituitary tumour removal 24.71 16.02 4 7509 15 46678534
Galactorrhoea 24.35 16.02 12 7501 3785 46674764
Maternal exposure during pregnancy 24.27 16.02 52 7461 102497 46576052
Death 24.07 16.02 12 7501 335536 46343013
Toxicity to various agents 23.85 16.02 3 7510 211763 46466786
Blood growth hormone abnormal 22.16 16.02 4 7509 32 46678517
Urine calcium/creatinine ratio increased 21.86 16.02 5 7508 140 46678409
Diabetes mellitus 21.63 16.02 33 7480 50032 46628517
Application site mass 20.93 16.02 4 7509 45 46678504
Chikungunya virus infection 19.77 16.02 5 7508 216 46678333
Normal newborn 19.21 16.02 12 7501 5989 46672560
Premature separation of placenta 19.16 16.02 8 7505 1720 46676829
Arteriovenous fistula 18.98 16.02 5 7508 254 46678295
Dopamine dysregulation syndrome 18.66 16.02 5 7508 271 46678278
Rash 18.61 16.02 18 7495 356494 46322055
Blood gonadotrophin decreased 18.38 16.02 3 7510 12 46678537
Secondary hypothyroidism 18.24 16.02 4 7509 92 46678457
Pulmonary artery occlusion 18.19 16.02 3 7510 13 46678536
Blood pressure increased 18.10 16.02 53 7460 126613 46551936
Secondary hypogonadism 17.89 16.02 4 7509 101 46678448
Blood parathyroid hormone increased 17.79 16.02 9 7504 2999 46675550
Adrenocortical insufficiency acute 17.75 16.02 7 7506 1299 46677250
Multiple endocrine neoplasia Type 1 17.67 16.02 3 7510 16 46678533
Breast atrophy 17.67 16.02 3 7510 16 46678533
Hypopituitarism 17.60 16.02 6 7507 739 46677810
Retroperitoneal fibrosis 17.59 16.02 5 7508 338 46678211
Adjacent segment degeneration 17.37 16.02 3 7510 18 46678531
Blood pressure systolic increased 16.93 16.02 22 7491 28765 46649784
Mitral valve sclerosis 16.92 16.02 4 7509 130 46678419
Memory impairment 16.91 16.02 38 7475 77299 46601250
Headache 16.37 16.02 132 7381 478220 46200329
Blood sodium increased 16.18 16.02 8 7505 2541 46676008
Panic disorder 16.14 16.02 8 7505 2553 46675996
Cardiac valve sclerosis 16.11 16.02 3 7510 29 46678520
Pituitary enlargement 16.11 16.02 3 7510 29 46678520

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cerebrospinal fluid leakage 253.30 18.75 46 4517 408 29947507
Gambling disorder 189.13 18.75 46 4517 1794 29946121
Aortic valve incompetence 140.21 18.75 45 4518 4878 29943037
Insulin-like growth factor increased 111.94 18.75 27 4536 1014 29946901
Mitral valve incompetence 100.09 18.75 46 4517 13188 29934727
Pneumocephalus 83.51 18.75 14 4549 73 29947842
Visual pathway disorder 73.62 18.75 11 4552 22 29947893
Pituitary haemorrhage 72.09 18.75 14 4549 183 29947732
Cardiac valve disease 64.11 18.75 22 4541 2927 29944988
Prolactin-producing pituitary tumour 56.70 18.75 9 4554 31 29947884
Empty sella syndrome 54.16 18.75 9 4554 44 29947871
Tricuspid valve incompetence 50.03 18.75 25 4538 8598 29939317
Secondary hypogonadism 49.20 18.75 11 4552 294 29947621
Pituitary tumour 48.83 18.75 12 4551 487 29947428
Parkinson's disease 45.93 18.75 15 4548 1713 29946202
Jealous delusion 44.88 18.75 10 4553 263 29947652
Blood prolactin increased 44.60 18.75 14 4549 1408 29946507
Neoplasm progression 44.56 18.75 30 4533 17993 29929922
Needle issue 44.33 18.75 18 4545 3814 29944101
Hormone level abnormal 42.32 18.75 10 4553 343 29947572
Pleural effusion 42.03 18.75 54 4509 74012 29873903
Pleural fibrosis 40.27 18.75 13 4550 1431 29946484
Acromegaly 40.24 18.75 7 4556 47 29947868
Aortic valve sclerosis 37.23 18.75 11 4552 902 29947013
Blood growth hormone increased 36.37 18.75 8 4555 198 29947717
Performance enhancing product use 35.33 18.75 7 4556 102 29947813
Intracranial hypotension 34.09 18.75 8 4555 266 29947649
Cortisol free urine increased 33.80 18.75 5 4558 9 29947906
Blood corticotrophin increased 32.36 18.75 6 4557 60 29947855
Hemianopia 31.48 18.75 9 4554 657 29947258
Cardiac valve sclerosis 31.16 18.75 4 4559 0 29947915
Glucose tolerance decreased 30.99 18.75 6 4557 77 29947838
Gambling 30.09 18.75 7 4556 224 29947691
Sudden onset of sleep 30.06 18.75 8 4555 447 29947468
Impulse-control disorder 28.74 18.75 10 4553 1385 29946530
Hypersexuality 28.11 18.75 10 4553 1477 29946438
Persecutory delusion 28.04 18.75 11 4552 2129 29945786
Autoimmune thyroiditis 27.70 18.75 9 4554 1011 29946904
Borderline personality disorder 26.54 18.75 7 4556 378 29947537
Cardiomegaly 26.30 18.75 20 4543 14489 29933426
Pleurisy 25.53 18.75 13 4550 4647 29943268
IIIrd nerve paralysis 25.44 18.75 7 4556 444 29947471
Hallucination 25.06 18.75 34 4529 49025 29898890
Injection site erosion 24.80 18.75 5 4558 80 29947835
Reversible cerebral vasoconstriction syndrome 24.47 18.75 6 4557 241 29947674
Dopamine dysregulation syndrome 24.35 18.75 7 4556 521 29947394
Aortic valve disease 23.01 18.75 8 4555 1105 29946810
Death 23.00 18.75 13 4550 357270 29590645
Therapeutic response decreased 22.72 18.75 23 4540 24326 29923589
Mitral valve sclerosis 22.45 18.75 5 4558 131 29947784
Libido increased 21.11 18.75 7 4556 837 29947078
Blood testosterone decreased 20.47 18.75 11 4552 4385 29943530
Blood growth hormone abnormal 20.08 18.75 3 4560 6 29947909

Pharmacologic Action:

SourceCodeDescription
ATC G02CB03 GENITO URINARY SYSTEM AND SEX HORMONES
OTHER GYNECOLOGICALS
OTHER GYNECOLOGICALS
Prolactine inhibitors
ATC N04BC06 NERVOUS SYSTEM
ANTI-PARKINSON DRUGS
DOPAMINERGIC AGENTS
Dopamine agonists
FDA CS M0007652 Ergolines
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:48407 antiparkinson agent
CHEBI has role CHEBI:51065 agonista dopaminergico
MeSH PA D018726 Anti-Dyskinesia Agents
MeSH PA D000978 Antiparkinson Agents
MeSH PA D002491 Central Nervous System Agents
MeSH PA D015259 Dopamine Agents
MeSH PA D018491 Dopamine Agonists
MeSH PA D018377 Neurotransmitter Agents
FDA EPC N0000175827 Ergot Derivative

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Hyperprolactinemia indication 237662005 DOID:12700
Heart valve disorder contraindication 368009 DOID:4079
Severe pre-eclampsia contraindication 46764007
Retroperitoneal fibrosis contraindication 49120005
Fibrosis of lung contraindication 51615001 DOID:3770
Fibrosis of pericardium contraindication 194965002
Disease of liver contraindication 235856003 DOID:409
Breastfeeding (mother) contraindication 413712001
Hypertensive urgency contraindication 443482000
Occlusive Vascular Disease contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 12.83 acidic
pKa2 13.48 acidic
pKa3 7.88 Basic
pKa4 5.97 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
D(2) dopamine receptor GPCR AGONIST Ki 9.20 IUPHAR CHEMBL
D(3) dopamine receptor GPCR AGONIST Ki 9.10 IUPHAR
5-hydroxytryptamine receptor 2A GPCR AGONIST Ki 8.20 IUPHAR
5-hydroxytryptamine receptor 1D GPCR AGONIST Ki 8.10 IUPHAR
Alpha-2A adrenergic receptor GPCR ANTAGONIST Ki 7.90 IUPHAR
D(1B) dopamine receptor GPCR AGONIST Ki 7.70 IUPHAR
5-hydroxytryptamine receptor 1A GPCR AGONIST Ki 7.70 IUPHAR
Alpha-2C adrenergic receptor GPCR ANTAGONIST Ki 7.70 IUPHAR
D(4) dopamine receptor GPCR AGONIST Ki 7.30 IUPHAR
Alpha-2B adrenergic receptor GPCR ANTAGONIST Ki 7.10 IUPHAR
D(1A) dopamine receptor GPCR AGONIST Ki 6.70 IUPHAR
Alpha-1A adrenergic receptor GPCR ANTAGONIST Ki 6.50 IUPHAR
5-hydroxytryptamine receptor 1B GPCR AGONIST Ki 6.30 IUPHAR
5-hydroxytryptamine receptor 2C GPCR AGONIST Ki 6.20 IUPHAR
Alpha-1B adrenergic receptor GPCR Ki 7.22 PDSP
Alpha-1D adrenergic receptor GPCR Ki 6.78 PDSP
5-hydroxytryptamine receptor 2B GPCR Ki 8.85 CHEMBL

External reference:

IDSource
4021014 VUID
N0000148483 NUI
D00987 KEGG_DRUG
4021014 VANDF
C0526034 UMLSCUI
CHEBI:3286 CHEBI
CHEMBL1201087 ChEMBL_ID
DB00248 DRUGBANK_ID
D000077465 MESH_DESCRIPTOR_UI
5860 INN_ID
54746 PUBCHEM_CID
37 IUPHAR_LIGAND_ID
LL60K9J05T UNII
134895 RXNORM
4317 MMSL
6425 MMSL
73532 MMSL
d04112 MMSL
005446 NDDF
109139002 SNOMEDCT_US
386979007 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 0093-5420 TABLET 0.50 mg ORAL ANDA 25 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 49884-673 TABLET 0.50 mg ORAL ANDA 21 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50090-3157 TABLET 0.50 mg ORAL ANDA 25 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50090-3951 TABLET 0.50 mg ORAL ANDA 21 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 50742-118 TABLET 0.50 mg ORAL ANDA 23 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 59762-1005 TABLET 0.50 mg ORAL NDA AUTHORIZED GENERIC 22 sections
Cabergoline HUMAN PRESCRIPTION DRUG LABEL 1 70518-2379 TABLET 0.50 mg ORAL ANDA 23 sections